In early May, as the world held its breath in anticipation of the nuclear disarmament discussions between US President Donald Trump and North Korean dictator Kim Jong Un and struggled to digest Trump's decision to pull the United States out of the Iran nuclear deal, an international meeting on the subject was winding up in Geneva. Over several days, representatives of dozens of states discussed preparations for the fifth review conference of the Nuclear Non-Proliferation Treaty (NPT) scheduled to take place in 2020.
As always, the Egyptian representative attacked Israel for refusing to sign the treaty. The Iranian ambassador to the International Atomic Energy Agency (IAEA), Raza Najafi, took the opportunity to take a dig at the United States for its nuclear cooperation with the “Zionist regime.” The Iranian news agency reported that Najafi stressed his country’s full commitment to the treaty.
Also as always, Israel observed the scene from the sidelines, just as it did last July when 122 states signed a treaty banning a series of nuclear weapons-related activity such as attempts to develop, test, produce, spread and stockpile such weapons. Obviously, the world’s nine nuclear states did not append their signatures to the document. Israel, which is not a member of this club, was also absent from the list of signatories. Iran signed.
For over five decades, Israel has been playing both sides. Despite numerous and persistent indications that not all of its nuclear reactors are designed for peaceful use, Israel does not admit to having a bomb. In fact, for years, it has maintained a policy of ambiguity, neither denying nor admitting possession of a nuclear bomb. Last week, The New Yorker reported that shortly after assuming office, Trump agreed to a request by Prime Minister Benjamin Netanyahu to sign a letter promising not to press Israel to give up its nuclear weapons. According to the report, three previous residents of the White House had signed similar commitments.
AL-MONITOR All-Access gives you unlimited access to all our journalism, the full Daily Briefing, exclusive interviews, premium newsletters, and live events — for less than $2/week.